8-K 1 a96633e8vk.htm FORM 8-K Aastrom Biosciences, Inc.
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     
Date of Report (Date of earliest event reported)
  February 19, 2004

Aastrom Biosciences, Inc.

(Exact name of registrant as specified in charter)
         
Michigan   0-22025   94-3096597
  		 
  		 
 
(State or other jurisdiction
of incorporation) 		  (Commission
File Number) 		  (IRS Employer
Identification No.)
     
24 Frank Lloyd Wright Drive, P.O. Box 376, Ann Arbor Michigan   48106
  		 
 
(Address of principal executive offices)   (Zip Code)
     
Registrant’s telephone number, including area code
  (734) 930-5555

Not Applicable

(Former name or former address, if changed since last report)

 

TABLE OF CONTENTS

Item 7. Financial Statements and Exhibits.
Item 9. Regulation FD Disclosure.
SIGNATURES
EXHIBIT INDEX
EXHIBIT 99

Table of Contents

Item 7. Financial Statements and Exhibits.

     
Exhibit    
No.
   Description
99
  Slides used in presentations

Item 9. Regulation FD Disclosure.

Attached hereto as Exhibit 99, which is incorporated herein by reference, is a copy of certain slides used by the Company in making a conference presentation and that are expected to be used in subsequent presentations to interested parties, including analysts and shareholders. This information is not “filed” pursuant to the Securities Exchange Act and is not incorporated by reference into any Securities Act registration statements. Additionally, the submission of this report on Form 8-K is not an admission as to the materiality of any information in this report that is required to be disclosed solely by Regulation FD. Any information in this report supercedes inconsistent or outdated information contained in earlier Regulation FD disclosures.

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
  Aastrom Biosciences, Inc.
 		  
  By:   /s/ Alan M. Wright    
    Senior Vice President,   
Date: February 19, 2004    Administration and Financial Operations   

 

Table of Contents

         

EXHIBIT INDEX

     
Exhibit    
No.
   Description
99
  Slides used in presentations